June 09, 2025

Weight Loss Treatment Linked With Neovascular Age-Related Macular Degeneration in Diabetic Patients

Study inclusion criteria were patients age 66 or older who had diabetes and a minimum follow-up period of 12 months following this initial diagnosis.

Optometric Management

June 05, 2025

Gene Therapy for Stargardt Advances to Trial

VeonGen announces new name and progress in its VG801 clinical program, which targets genetic mutations linked to Stargardt disease.

Retinal Physician

June 02, 2025

Geographic Atrophy: Early Detection and Patient Awareness Matters

Learn about the essential steps optometrists can take to support patients with geographic atrophy and preserve vision.

Optometric Management

June 01, 2025

Preservation of Vision in GA in ARCHER Trial Continues Evaluation in ARCHER II

Discover the potential breakthrough in preserving vision in geographic atrophy presented by Dr. Priya Vakharia at the Retina World Congress.

Retinal Physician

January 01, 2023

Retinal Fluid Fluctuations in the Treatment of Neovascular AMD

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Retinal Physician

May 01, 2024

Unraveling Green Disease with the Optovue Solix AngioVue Disc Report

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Optometric Management

January 01, 2025

Clinical Trial Update January/February 2025

Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.

Retinal Physician

June 01, 2024

We Need to Talk About GA

Helping patients understand the risks of and treatments for geographic atrophy.

Optometric Management

April 24, 2025

FDA Rejects Extended Dosing Intervals for Eylea HD

The agency did not agree with Regeneron’s proposal to add dosing intervals greater than every 16 weeks, the maximum interval currently indicated for aflibercept 8 mg injections.

Retinal Physician